Sector News

Amgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary

May 20, 2015
Life sciences
/PRNewswire/ – Amgen today announced the appointment of Jonathan P. Graham as senior vice president, general counsel and secretary, effective July 13, 2015. He will be responsible for Amgen’s legal operations, reporting to Robert A. Bradway, chairman and chief executive officer. Graham will succeed David J. Scott who is retiring Aug. 31, 2015.
 
Graham, 55, joins Amgen from Danaher Corporation, where he has served as senior vice president and general counsel, responsible for all legal, governance, regulatory, risk, and compliance matters.
 
Previously, Graham was vice president, litigation and legal policy at General Electric Company and a partner at Williams & Connolly LLP. He also served as a law clerk to the Honorable Joseph T. Sneed, U.S. Court of Appeals for the Ninth Circuit. Graham received his bachelor’s degree from Pitzer College and his J.D. from the University of Texas School of Law, where he was editor-in-chief of the Texas Law Review. 
 
Bradway said, “We are excited to have Jon join our team.  His proven leadership skills and depth of experience will serve us well as we drive our agenda for growth.”
 
Source: Amgen

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.